Ardelyx Q2 2024 Earnings Report $4.74 +0.08 (+1.72%) (As of 12:58 PM ET) Earnings HistoryForecast Ardelyx EPS ResultsActual EPS-$0.07Consensus EPS -$0.11Beat/MissBeat by +$0.04One Year Ago EPS-$0.08Ardelyx Revenue ResultsActual Revenue$73.20 millionExpected Revenue$55.03 millionBeat/MissBeat by +$18.17 millionYoY Revenue Growth+228.30%Ardelyx Announcement DetailsQuarterQ2 2024Date8/1/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseARDX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Ardelyx Earnings HeadlinesArdelyx, Inc. (NASDAQ:ARDX) Given Consensus Rating of "Moderate Buy" by BrokeragesDecember 12, 2024 | americanbankingnews.comLeerink Partnrs Increases Earnings Estimates for ArdelyxDecember 8, 2024 | americanbankingnews.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.December 18, 2024 | Crypto Swap Profits (Ad)Potential Growth for Ardelyx’s Ibsrela Amidst Market VolatilityDecember 7, 2024 | markets.businessinsider.comArdelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save ItNovember 24, 2024 | seekingalpha.comArdelyx to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNovember 20, 2024 | globenewswire.comSee More Ardelyx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ardelyx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ardelyx and other key companies, straight to your email. Email Address About ArdelyxArdelyx (NASDAQ:ARDX), a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.View Ardelyx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
